ATE209206T1 - Heterocyclisch substituierte cyclopentanderivate. - Google Patents

Heterocyclisch substituierte cyclopentanderivate.

Info

Publication number
ATE209206T1
ATE209206T1 AT96918151T AT96918151T ATE209206T1 AT E209206 T1 ATE209206 T1 AT E209206T1 AT 96918151 T AT96918151 T AT 96918151T AT 96918151 T AT96918151 T AT 96918151T AT E209206 T1 ATE209206 T1 AT E209206T1
Authority
AT
Austria
Prior art keywords
derivatives
heterocyclic substituted
compounds
cyclopentan
substituted cyclopentan
Prior art date
Application number
AT96918151T
Other languages
English (en)
Inventor
Shripad S Bhagwat
Marlon Daniel Cowart
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE209206T1 publication Critical patent/ATE209206T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT96918151T 1995-06-07 1996-06-06 Heterocyclisch substituierte cyclopentanderivate. ATE209206T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47248695A 1995-06-07 1995-06-07
US08/651,882 US6143749A (en) 1995-06-07 1996-06-04 Heterocyclic substituted cyclopentane compounds
PCT/US1996/009042 WO1996040686A1 (en) 1995-06-07 1996-06-06 Heterocyclic substituted cyclopentane compounds

Publications (1)

Publication Number Publication Date
ATE209206T1 true ATE209206T1 (de) 2001-12-15

Family

ID=27043790

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96918151T ATE209206T1 (de) 1995-06-07 1996-06-06 Heterocyclisch substituierte cyclopentanderivate.

Country Status (11)

Country Link
US (1) US6143749A (de)
EP (1) EP0873340B1 (de)
JP (1) JP2000501694A (de)
AT (1) ATE209206T1 (de)
CA (1) CA2220006A1 (de)
DE (1) DE69617273T2 (de)
DK (1) DK0873340T3 (de)
ES (1) ES2168479T3 (de)
MX (1) MX9709718A (de)
PT (1) PT873340E (de)
WO (1) WO1996040686A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674998A (en) * 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
US5721356A (en) * 1989-09-15 1998-02-24 Gensia, Inc. Orally active adenosine kinase inhibitors
CH690773A5 (de) * 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
GB9704948D0 (en) 1997-03-11 1997-04-30 Knoll Ag Therapeutic agents
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
ATE242245T1 (de) * 1997-03-19 2003-06-15 Basf Ag Pyrrolo(2,3-d)pyrimidine und ihre verwendung als tyrosinkinase-inhibitoren
IL131618A0 (en) * 1997-04-16 2001-01-28 Abbott Lab 5,7-Disubstituted aminopyrido [2,3-D] pyrimidine compounds and their use as adenosine kinase inhibitors
SK3842001A3 (en) * 1998-09-18 2002-04-04 Basf Ag Pyrrolopyrimidines as protein kinase inhibitors (revised)
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
US7071199B1 (en) 1999-09-17 2006-07-04 Abbott Gmbh & Cco. Kg Kinase inhibitors as therapeutic agents
AU2000240570A1 (en) * 2000-03-29 2001-10-08 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
GB0128885D0 (en) * 2001-12-03 2002-01-23 Merck Sharp & Dohme Therapeutic agents
WO2005044835A1 (en) * 2003-10-27 2005-05-19 Genelabs Technologies, Inc. METHODS FOR PREPARING 7-(2'-SUBSTITUTED-ß-D-RIBOFURANOSYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES
US7345034B2 (en) * 2004-04-07 2008-03-18 Abbott Laboratories Azacyclosteroid histamine-3 receptor ligands
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
TW200738725A (en) * 2006-01-25 2007-10-16 Osi Pharm Inc Unsaturated mTOR inhibitors
PE20080361A1 (es) * 2006-04-21 2008-06-03 Novartis Ag Compuestos derivados de purina como activadores del receptor de adenosina a2a
US9487494B2 (en) * 2007-11-23 2016-11-08 Leo Pharma A/S Cyclic hydrocarbon compounds for the treatment of diseases
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
GB201115853D0 (en) * 2011-09-14 2011-10-26 Proximagen Ltd New enzyme inhibitor compounds
AU2011376717A1 (en) 2011-09-14 2014-03-20 Proximagen Limited New enzyme inhibitor compounds
JP6397897B2 (ja) * 2013-05-14 2018-09-26 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ ピロロ［２，３−ｄ］ピリミジン誘導体、その製造方法及びキナーゼ阻害剤としてのその使用
TWI870767B (zh) 2015-08-26 2025-01-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
MA41559A (fr) 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
ES2775751T3 (es) 2016-02-23 2020-07-28 Taiho Pharmaceutical Co Ltd Nuevo compuesto de pirimidina condensada o sal del mismo
MA43671A (fr) 2016-03-10 2018-11-28 Janssen Pharmaceutica Nv Analogues de nucléosides substitués destinés à être utilisés en tant qu'inhibiteurs de prmt5
CA2969295A1 (en) * 2016-06-06 2017-12-06 Pfizer Inc. Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
ES2966316T3 (es) 2016-09-14 2024-04-19 Janssen Pharmaceutica Nv Inhibidores bicíclicos fusionados de interacción de MENIN-MLL
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
BR112019004691A2 (pt) 2016-09-14 2019-06-25 Janssen Pharmaceutica Nv inibidores bicíclicos em espiro da interação menina-mll
WO2018065365A1 (en) 2016-10-03 2018-04-12 Janssen Pharmaceutica Nv Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
MX2019003843A (es) * 2016-10-03 2019-06-24 Janssen Pharmaceutica Nv Análogos novedosos de carbanucleósidos sustituidos de sistema anular monocíclico y bicíclico para su uso como inhibidores de prmt5.
KR102513564B1 (ko) 2016-12-15 2023-03-22 얀센 파마슈티카 엔.브이. 메닌-mll 상호작용의 아제판 억제제
CA3049739A1 (en) 2017-02-27 2018-08-30 Janssen Pharmaceutica Nv Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor
WO2018160824A1 (en) * 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
AU2018322286B2 (en) 2017-08-21 2022-03-10 Taiho Pharmaceutical Co., Ltd. Fusion protein of DCTN1 protein with RET protein
BR112020010815A2 (pt) * 2017-12-08 2020-11-10 Janssen Pharmaceutica Nv análogos espirobicíclicos
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
JP7609798B2 (ja) * 2019-03-25 2025-01-07 カリフォルニア インスティチュート オブ テクノロジー Ｐｒｍｔ５インヒビター及びその使用
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用ｐｒｍｔ５抑制劑治療癌症之方法
BR112021024457A2 (pt) 2019-06-12 2022-01-18 Janssen Pharmaceutica Nv Intermediários espirobicíclicos
CN118255773A (zh) 2019-12-19 2024-06-28 詹森药业有限公司 取代的直链螺环衍生物
CN111320634A (zh) * 2020-04-14 2020-06-23 浙江工业大学 一种乙酰氧取代的吡咯并[2,3-d]嘧啶衍生物的制备方法
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3551428A (en) * 1956-02-10 1970-12-29 Ciba Geigy Corp New 1- (or 2-) substituted 4-mercapto-pyrazolo(3,4-d)pyrimidines
US3296261A (en) * 1965-03-09 1967-01-03 Bristol Myers Co 6-hydroxy-pyrimidine-5-acetamides
US3311628A (en) * 1965-03-09 1967-03-28 Bristol Myers Co Derivatives of pyrrolo [2, 3-d] pyrimidine
US5378825A (en) * 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5223618A (en) * 1990-08-13 1993-06-29 Isis Pharmaceuticals, Inc. 4'-desmethyl nucleoside analog compounds
FI933303L (fi) * 1991-01-23 1993-08-31 Gensia Inc Adenosinkinasinhibitorer
EP0521463A3 (en) * 1991-07-04 1993-04-14 Hoechst Aktiengesellschaft Substituted cyclic cycloalkyltriols, process, intermediates for their preparation and their use as antiviral and antiparasitic agents
AU4845193A (en) * 1992-09-11 1994-04-12 Regents Of The University Of California, The Adenosine analogues and method of increasing adenosine release
US6765008B1 (en) * 1992-12-17 2004-07-20 Pfizer Inc Pyrrolopyrimidines as CRF antagonists
AU673055B2 (en) * 1993-02-03 1996-10-24 Gensia, Inc. Adenosine kinase inhibitors comprising lyxofuranosyl derivatives
IL108523A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain

Also Published As

Publication number Publication date
CA2220006A1 (en) 1996-12-19
JP2000501694A (ja) 2000-02-15
PT873340E (pt) 2002-05-31
EP0873340B1 (de) 2001-11-21
DE69617273T2 (de) 2002-07-25
DE69617273D1 (de) 2002-01-03
MX9709718A (es) 1998-07-31
EP0873340A1 (de) 1998-10-28
ES2168479T3 (es) 2002-06-16
US6143749A (en) 2000-11-07
DK0873340T3 (da) 2002-05-21
WO1996040686A1 (en) 1996-12-19

Similar Documents

Publication Publication Date Title
ATE209206T1 (de) Heterocyclisch substituierte cyclopentanderivate.
ATE267200T1 (de) Bicyclische kinase inhibitoren
ID27535A (id) Turunan pirasola sebagai inhibitor p-38 map kinase
MX9707431A (es) Inhibidores de la proteina cinasa c.
TR199800759T2 (xx) Protein Kinaz C �nhibit�r�.
DK0657458T3 (da) Inhibitorer af proteinkinase-C
EA199900373A2 (ru) Фармацевтические композиции
DE69620161D1 (de) Thrombininhibitoren
TR199900049T2 (xx) Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler.
DK0911333T3 (da) Pyrazol [4,3-d]pyrimidinderivater og farmaceutiske præparater, der indeholder disse
DE60142921D1 (de) Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
EA200001176A1 (ru) Гетероциклические ингибиторы p38
DE69528528D1 (de) Thrombin-inhibitoren
ATE217865T1 (de) Verbindungen zur hemmung von phosphodiesrerase iv
AR024138A1 (es) Inhibidores de la proliferacion celular
TR200101756T2 (tr) Protein kinaz inhibitörleri olarak 4,5-pirazinoksindoller.
PT1282418E (pt) Utilizacao de derivados pirazolo para o tratamento da infertilidade
ATE293964T1 (de) Zusammensetzungen und verfahren zur behinderung der entladung von nematokyste
GEP20084346B (en) Protein kinase c inhibitors
FI970318A0 (fi) Antiproliferatiivisina aineina ja Garft-inhibiitoreina käyttökelpoisia yhdisteitä
AR028186A1 (es) Compuestos de 5-aril-1, 2, 4-triazol inhibidores de ciclooxigenasa-2 y composiciones farmaceuticas que comprenden dichos compuestos

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee